Literature DB >> 1438762

High-attenuation lymphadenopathy in AIDS patients: significance of findings at CT.

B R Herts1, A J Megibow, B A Birnbaum, G K Kanzer, M E Noz.   

Abstract

A retrospective evaluation was performed of the location and attenuation characteristics of abdominal and pelvic lymphadenopathy, identified at dynamic sequential bolus computed tomography (CT) in 69 patients with acquired immunodeficiency syndrome (AIDS). Lymph node appearance at CT was characterized as hyperattenuating, isoattenuating, or hypoattenuating relative to the iliopsoas muscle. The significance of finding hyperattenuating adenopathy in the patient population was evaluated. Thirty-three patients had hyperattenuating adenopathy, including 26 with the epidemic form of Kaposi sarcoma (KS). Of 38 patients with epidemic KS, 26 had hyperattenuating, 11 had isoattenuating, and one had hypoattenuating lymphadenopathy. The positive predictive value of hyperattenuating adenopathy for epidemic KS was 79%. These findings were statistically significant at the 95% confidence interval (P < .005). Hyperattenuating lymphadenopathy, identified on dynamic sequential bolus CT scans in AIDS patients, was seen with disseminated KS in approximately 80% of cases.

Entities:  

Mesh:

Year:  1992        PMID: 1438762     DOI: 10.1148/radiology.185.3.1438762

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

Review 1.  State of the art: gastrointestinal malignancies in the human immunodeficiency virus (HIV) population.

Authors:  Mary Koshy; John Kauh; Clifford Gunthel; Melissa Joyner; Jerome Landry; Charles R Thomas
Journal:  Int J Gastrointest Cancer       Date:  2005

Review 2.  Imaging techniques for Kaposi's sarcoma.

Authors:  D O'Mahony; Ah Gandjbakche; M Hassan; A Vogel; R Yarchoan
Journal:  J HIV Ther       Date:  2008-09

Review 3.  The acute abdomen in the immune compromised host.

Authors:  Simon P Spencer; Niall Power
Journal:  Cancer Imaging       Date:  2008-04-22       Impact factor: 3.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.